Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug’s outlook.

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio cream